Outcomes of pars plana vitrectomy with subretinal tissue plasminogen activator injection and pneumatic displacement of fovea-involving submacular haemorrhage
- PMID: 32201733
- PMCID: PMC7076260
- DOI: 10.1136/bmjophth-2019-000394
Outcomes of pars plana vitrectomy with subretinal tissue plasminogen activator injection and pneumatic displacement of fovea-involving submacular haemorrhage
Abstract
Objective: Fovea-involving subretinal haemorrhage is challenging to manage with uncertain visual outcomes. We reviewed outcomes of patients with fovea-involving macular haemorrhage treated with pars plana vitrectomy (PPV) and subretinal tissue plasminogen activator (tPA) with pneumatic displacement.
Methods and analysis: This is a retrospective interventional case series. All patients with submacular haemorrhage who underwent PPV with subretinal tPA injection were included. Reasons for exclusion encompassed patients who underwent intravitreal tPA injection in the office without surgery, insufficient follow-up or documentation. Primary outcomes of interest were postoperative visual acuity (VA) at month 1 and 3. Secondary outcomes were median VA at month 3 by location of haemorrhage and underlying diagnosis.
Results: Thirty-seven total patients were included. The mean age was 68.2 years, with 54.1% (20/37) females. The most common aetiology was exudative macular degeneration (43.2%), followed by undifferentiated choroidal neovascularisation (CNV) (18.9%), polypoidal choroidal vasculopathy (18.9%), traumatic CNV (10.8%), macroaneurysm (5.4%) and proliferative diabetic retinopathy (2.7%). Median preoperative VA was 20/2000, postoperative month 1 was 20/347 (p<0.01), improving to 20/152 (p<0.01) at month 3. Proportion of patients gaining vision 3+ lines in vision was 15/36 (42%). Mean preoperative central subfield thickness on optical coherence tomography was 512.2 µm for sub-retinal pigment epithelium haemorrhage and 648.2 µm for subretinal haemorrhage (p=0.48). Difference in VA by diagnosis was not significant (p=0.60).
Conclusions: PPV with subretinal tPA injection and pneumatic displacement of submacular haemorrhage offers modest visual recovery for a diverse group of patients. Location of haemorrhage or specific diagnosis may not predict outcome.
Keywords: macula; neovascularisation; retina; treatment surgery.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: RBR reports consulting fees from Optovue, Boehringer- Ingelheim, NanoRetina, Bayer, Regeneron, CellView, and Astellas. He holds patents with Optovue and has a personal financial interest in Opticology and Guardion Health. None of the other authors report any relevant conflicts or proprietary interest in the results of this study.
Figures


Similar articles
-
Displacement of Submacular Hemorrhage Using Subretinal Cocktail Injection versus Pneumatic Displacement: A Real-World Comparative Study.Ophthalmologica. 2024;247(2):118-132. doi: 10.1159/000537953. Epub 2024 Feb 26. Ophthalmologica. 2024. PMID: 38408445 Free PMC article.
-
Pneumatic Displacement of Submacular Hemorrhage with Subretinal Air and Tissue Plasminogen Activator: Initial United States Experience.Ophthalmol Retina. 2018 Mar;2(3):180-186. doi: 10.1016/j.oret.2017.07.012. Epub 2017 Sep 28. Ophthalmol Retina. 2018. PMID: 31047581
-
Visual Recovery and Prognosis in the Treatment of Submacular Hemorrhage due to Polypoidal Choroidal Vasculopathy and Retinal Arterial Macroaneurysm: A Retrospective Study.Int J Clin Pract. 2023 Jun 12;2023:3880297. doi: 10.1155/2023/3880297. eCollection 2023. Int J Clin Pract. 2023. PMID: 37342617 Free PMC article.
-
Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature.Surv Ophthalmol. 2016 Jan-Feb;61(1):18-32. doi: 10.1016/j.survophthal.2015.04.004. Epub 2015 Jul 23. Surv Ophthalmol. 2016. PMID: 26212151 Review.
-
Traumatic submacular hemorrhage: available treatment options and synthesis of the literature.Int J Retina Vitreous. 2019 Dec 11;5:48. doi: 10.1186/s40942-019-0200-0. eCollection 2019. Int J Retina Vitreous. 2019. PMID: 31890278 Free PMC article. Review.
Cited by
-
[Management of submacular hemorrhage : What, when, how?].Ophthalmologe. 2020 Sep;117(9):848-857. doi: 10.1007/s00347-020-01192-5. Ophthalmologe. 2020. PMID: 32767098 Review. German.
-
Incidence of macular hole in patients undergoing pars plana vitrectomy for submacular hemorrhage.PLoS One. 2025 Feb 27;20(2):e0319266. doi: 10.1371/journal.pone.0319266. eCollection 2025. PLoS One. 2025. PMID: 40014591 Free PMC article.
-
Effects of Combination Therapy with Intravitreal Ranibizumab and Tissue Plasminogen Activator for Neovascular Age-Related Macular Degeneration.J Clin Med. 2024 Apr 21;13(8):2417. doi: 10.3390/jcm13082417. J Clin Med. 2024. PMID: 38673690 Free PMC article.
-
Differences in clinical characteristics and treatment outcomes of submacular hemorrhage caused by age-related macular degeneration and retinal macroaneurysms: A multicenter survey from the Japan Clinical Retina Study (J-CREST) group.PLoS One. 2022 Sep 29;17(9):e0274508. doi: 10.1371/journal.pone.0274508. eCollection 2022. PLoS One. 2022. PMID: 36173964 Free PMC article.
-
Clinical Outcomes of Retinal Arterial Macroaneurysms With Vitreous Hemorrhage Treated With Observation, Antivascular Endothelial Growth Factor Intravitreal Injections, or Pars Plana Vitrectomy.J Vitreoretin Dis. 2023 Oct 3;7(6):483-489. doi: 10.1177/24741264231200734. eCollection 2023 Nov-Dec. J Vitreoretin Dis. 2023. PMID: 37974920 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous